Rachel Ruggeri
Known title: DirectorCIK: 0001842880
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Starbucks Faces Growing Problem Despite Returning Customers. Starbucks is dealing with a growing problem even as customers return, according to recent reports. The stock has risen 15% year‑to‑date, prompting questions about further upside. Jim Cramer noted that Starbucks can rise on its own, highlighting the company's resilience.
Transaction History
| SYK | ▲ Buy | Grant | 762 | $0 | 5/6/2026 | View on chart |
| SYK | ▲ Buy | Grant | 560 | $0 | 5/8/2025 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,289 | $146K | 2/18/2025 | View on chart |
| SBUX | ▼ Sell | Open Market | 1,491 | $148K | 11/21/2024 | View on chart |
| SBUX | ▲ Buy | Grant | 18,302 | $0 | 11/19/2024 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 2,335 | $234K | 11/18/2024 | View on chart |
| SBUX | ▼ Sell | Open Market | 1,452 | $144K | 11/15/2024 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,927 | $191K | 11/14/2024 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 4,957 | $497K | 11/11/2024 | View on chart |
| SBUX | ▲ Buy | Grant | 10,907 | $0 | 11/11/2024 | View on chart |
| SBUX | ▼ Sell | Open Market | 3,290 | $300K | 8/13/2024 | View on chart |
| SBUX | ▼ Sell | Open Market | 3,750 | $300K | 5/22/2024 | View on chart |
| SYK | ▲ Buy | Grant | 653 | $0 | 5/9/2024 | View on chart |
| SBUX | ▼ Sell | Open Market | 3,221 | $300K | 3/4/2024 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 2,279 | $238K | 11/20/2023 | View on chart |
| SBUX | ▼ Sell | Open Market | 842 | $89K | 11/16/2023 | View on chart |
| SBUX | ▼ Sell | Open Market | 504 | $53K | 11/15/2023 | View on chart |
| SBUX | ▲ Buy | Grant | 18,939 | $0 | 11/14/2023 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 2,799 | $290K | 11/13/2023 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,633 | $170K | 11/10/2023 | View on chart |
| SBUX | ▲ Buy | Grant | 6,030 | $0 | 11/7/2023 | View on chart |
| SBUX | ▼ Sell | Open Market | 679 | $68K | 6/21/2023 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,093 | $111K | 6/15/2023 | View on chart |
| SBUX | ▼ Sell | Open Market | 736 | $78K | 2/21/2023 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,198 | $129K | 2/16/2023 | View on chart |
| SBUX | ▼ Sell | Open Market | 3,960 | $422K | 1/9/2023 | View on chart |
| SBUX | ▲ Buy | Grant | 22,460 | $0 | 11/18/2022 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 234 | $23K | 11/11/2022 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 990 | $95K | 11/10/2022 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 1,068 | $79K | 6/15/2022 | View on chart |
| SBUX | ▼ Sell | Tax Withholding | 229 | $26K | 11/11/2021 | View on chart |
| SBUX | ▲ Buy | Grant | 15,894 | $0 | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.